I think the TRIPP-FX study is really important. Two of the main things holding OSL back are the lack of an RCT AND the label restriction based on the (wrong) original punt by previous management that gemcitabine would be the dominant chemo. If the trial is successful and OSL extends its label to folfirinox, the use will expand significantly and quickly because that's what most pancreatic cancers are treated with. And if it has a successful RCT funding bodies will have to take notice with regards to reimbursement. The GBA study in Germany essentially would mimic this study with the exception that the German Government would fund it (and not Oncosil). And that would be 2 RCTs and it would be faster because Germany is so big. I have tried to find out if the study can report interim findings, given it obviously isn;t blinded, but I haven't been able to. I suspect not.
OSL Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
